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Background: BCIS-1 was a multicenter randomized controlled trial of elective intra-aortic balloon counterpulsation (IABC) during percutaneous 
coronary intervention in patients with severe left ventricular impairment and extensive coronary disease. There was no difference in the primary 
endpoint of MACCE at hospital discharge, capped at 28 days. We report long-term all-cause mortality in this cohort.
Methods: 301 patients were randomized to receive PCI with elective IABP support (n=151) or without planned IABP support (n=150). All-cause 
mortality data were collected by tracking the databases held by the Office of National Statistics (in England and Wales) and the General Register 
Office (in Scotland). Analysis by treatment assignment is shown below; as treated data will be also be presented. Cumulative event rates were 
estimated by the Kaplan-Meier method and compared using an unadjusted Cox proportional hazards model.
Results:  The groups were balanced in terms of baseline characteristics (LVEF 23.6%, BCIS-1 Jeopardy score 10.3). Mortality data were available 
for the entire cohort at a median of 51 months (IQR 41, 58) from randomization. All-cause mortality at follow-up was 28% in the Elective IABP group 
and 38.7% in the group who had PCI without planned IABP support (HR 0.66, 95% CI: 0.44 - 0.98, p=0.04).
Conclusion:  Elective IABP support during PCI for severe ischemic cardiomyopathy was associated with a late mortality benefit compared to 
unsupported PCI, despite the lack of difference in early MACCE.
 
